Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Adjuvant immunotherapy can help reduce the likelihood of the skin cancer returning, but is more better or is less more?
Adding checkpoint inhibitors to chemotherapy before surgery and continuing them alone afterward reduces the risk of recurrence and death.
A chemotherapy-free regimen combining immunotherapy with an antibody-drug conjugate extended survival by 15 months.
Reducing the risk of this deadly skin cancer recurring after surgery is an important goal, notes the Melanoma Research Alliance.
Surgery for this rare cancer required the removal of Walther’s left eye. “This is my journey,” she said, “and I have to travel it.”
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
In the trial, immune checkpoint inhibitor nivolumab was given for a maximum of 1 year.
After radiation, immunotherapy and chemo for melanoma, he tried an experimental therapy that uses TILs, tumor-infiltrating lymphocytes.
Immunotherapy and … nothing else? Studies test a potential paradigm shift in treatment for some people with early stage cancers.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
Can a person’s immune system help prevent two types of non-small-cell lung cancer? Here’s how Robert Keith, MD, hopes to find out.
About 1 in 1,000 pregnant women is diagnosed with cancer. Do newer treatments, such as immunotherapy, work in this group of patients?
“It is a really important development for our patients."
An intravenous infusion of two immunotherapy drugs, Opdualag blocks activity of the proteins LAG-3 and PD-1.
Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.
Bill Evans, a melanoma survivor, turns his love of cycling into a community building and fundraising effort.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.